ALFA News
Straight from the exchange filing
Every announcement Shilpa Medicare has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Shilpa Medicare announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Shilpa Medicare receives SEC approval for OERIS, a world-first 5-day extended-release ondansetron injection with Indian patent protection valid until 2039.
Shilpa Medicare commissions an integrated ADC drug substance GMP facility in Dharwad, positioning it as a global CDMO partner with ₹11,561 Cr market valuation.
Shilpa Medicare commissions a state-of-the-art ADC GMP manufacturing facility in Dharwad. The new plant enhances CDMO capabilities in the oncology space.
Shilpa Medicare subsidiary Shilpa Biologicals commissions an ADC GMP facility in Dharwad; the parent company reports a TTM revenue of 1,538.14 crore rupees.
